The choreography of neuroinflammation in Huntington's disease

Trends in Immunology

Volumn 36, Issue 6, 2015, Pages 364-373

  Crotti, Andrea ^a   Glass, Christopher K ^b,c  

^a BIOGEN   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

Astrocytes; Huntington's disease; Macrophages; Microglia; Neuroinflammation

Indexed keywords

HUNTINGTIN; CYTOKINE; HTT PROTEIN, HUMAN; NERVE PROTEIN;

ASTROCYTE; CLINICAL FEATURE; HUMAN; HUNTINGTON CHOREA; MACROPHAGE; MICROGLIA; MONOCYTE; NERVOUS SYSTEM INFLAMMATION; NONHUMAN; PATHOGENESIS; PROTEIN EXPRESSION; REVIEW; ANIMAL; BIOLOGICAL MODEL; GENETICS; IMMUNOLOGY; INFLAMMATION; METABOLISM; MUTATION; NERVE CELL;

ANIMALS; CYTOKINES; HUMANS; HUNTINGTIN PROTEIN; HUNTINGTON DISEASE; INFLAMMATION; MICROGLIA; MODELS, IMMUNOLOGICAL; MUTATION; NERVE TISSUE PROTEINS; NEURONS;

EID: 84930822255     PISSN: 14714906     EISSN: 14714981     Source Type: Journal    
DOI: 10.1016/j.it.2015.04.007     Document Type: Review

References (104)

1. Hensley K. Neuroinflammation in Alzheimer's disease: mechanisms, pathologic consequences, and potential for therapeutic manipulation. J. Alzheimers Dis. 2010, 21:1-14.
2. Aguzzi A., et al. Microglia: scapegoat, saboteur, or something else?. Science 2013, 339:156-161.
3. Samii A., et al. Parkinson's disease. Lancet 2004, 363:1783-1793.
4. Schellenberg G.D., Montine T.J. The genetics and neuropathology of Alzheimer's disease. Acta Neuropathol. 2012, 124:305-323.
5. Silvestroni A., et al. Distinct neuroinflammatory profile in post-mortem human Huntington's disease. Neuroreport 2009, 20:1098-1103.
6. MacDonald M.E., et al. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 1993, 72:971-983.
7. Soulet D., Cicchetti F. The role of immunity in Huntington's disease. Mol. Psychiatry 2011, 16:889-902.
8. Rosas H.D., et al. Altered white matter microstructure in the corpus callosum in Huntington's disease: implications for cortical 'disconnection'. Neuroimage 2009, 49:2995-3004.
9. Pavese N., et al. Clinical correlates of levodopa-induced dopamine release in Parkinson disease: a PET study. Neurology 2006, 67:1612-1617.
10. Tai Y.F., et al. Microglial activation in presymptomatic Huntington's disease gene carriers. Brain 2007, 130:1759-1766.
11. Tai Y.F., et al. Imaging microglial activation in Huntington's disease. Brain Res. Bull. 2007, 72:148-151.
12. Bjorkqvist M., et al. A novel pathogenic pathway of immune activation detectable before clinical onset in Huntington's disease. J. Exp. Med. 2008, 205:1869-1877.
13. Sapp E., et al. Early and progressive accumulation of reactive microglia in the Huntington disease brain. J. Neuropathol. Exp. Neurol. 2001, 60:161-172.
14. Brennan W.A., et al. Regional mitochondrial respiratory activity in Huntington's disease brain. J. Neurochem. 1985, 44:1948-1950.
15. Tabrizi S.J., et al. Biochemical abnormalities and excitotoxicity in Huntington's disease brain. Ann. Neurol. 1999, 45:25-32.
16. Sorolla M.A., et al. Proteomic and oxidative stress analysis in human brain samples of Huntington disease. Free Radic. Biol. Med. 2008, 45:667-678.
17. Browne S.E., et al. Oxidative damage and metabolic dysfunction in Huntington's disease: selective vulnerability of the basal ganglia. Ann. Neurol. 1997, 41:646-653.
18. van den Bogaard S.J., et al. The role of iron imaging in Huntington's disease. Int. Rev. Neurobiol. 2013, 110:241-250.
19. van der Burg J.M., et al. Beyond the brain: widespread pathology in Huntington's disease. Lancet Neurol. 2009, 8:765-774.
20. Runne H., et al. Analysis of potential transcriptomic biomarkers for Huntington's disease in peripheral blood. Proc. Natl. Acad. Sci. U.S.A. 2007, 104:14424-14429.
21. Dalrymple A., et al. Proteomic profiling of plasma in Huntington's disease reveals neuroinflammatory activation and biomarker candidates. J. Proteome Res. 2007, 6:2833-2840.
22. Chang K.H., et al. Plasma inflammatory biomarkers for Huntington's disease patients and mouse model. Brain Behav. Immunity 2015, 44:121-127.
23. Wild E., et al. Abnormal peripheral chemokine profile in Huntington's disease. PLoS Curr. 2011, 3:1231.
24. Sanchez-Lopez F., et al. Oxidative stress and inflammation biomarkers in the blood of patients with Huntington's disease. Neurol. Res. 2012, 34:721-724.
25. Trager U., et al. JAK/STAT signalling in Huntington's disease immune cells. PLoS Curr. 2014, 5:125-134.
26. Weiss A., et al. Mutant huntingtin fragmentation in immune cells tracks Huntington's disease progression. J. Clin. Invest. 2012, 122:3731-3736.
27. Bushara K.O., et al. Antigliadin antibodies in Huntington's disease. Neurology 2004, 62:132-133.
28. Lee D.H., et al. Increase of angiotensin II type 1 receptor auto-antibodies in Huntington's disease. Mol. Neurodegener. 2014, 9:49.
29. Lawson L.J., et al. Heterogeneity in the distribution and morphology of microglia in the normal adult mouse brain. Neuroscience 1990, 39:151-170.
30. Ransohoff R.M., Perry V.H. Microglial physiology: unique stimuli, specialized responses. Annu. Rev. Immunol. 2009, 27:119-145.
31. Nimmerjahn A., et al. Resting microglial cells are highly dynamic surveillants of brain parenchyma in vivo. Science 2005, 308:1314-1318.
32. Weinstein J.R., et al. Microglia in ischemic brain injury. Future Neurol. 2010, 5:227-246.
33. Hanisch U.K., Kettenmann H. Microglia: active sensor and versatile effector cells in the normal and pathologic brain. Nat. Neurosci. 2007, 10:1387-1394.
34. Crotti A., et al. Mutant Huntingtin promotes autonomous microglia activation via myeloid lineage-determining factors. Nat. Neurosci. 2014, 4:513-521.
35. Franciosi S., et al. Age-dependent neurovascular abnormalities and altered microglial morphology in the YAC128 mouse model of Huntington disease. Neurobiol. Dis. 2011, 45:438-449.
36. Ginhoux F., et al. Fate mapping analysis reveals that adult microglia derive from primitive macrophages. Science 2010, 330:841-845.
37. Schulz C., et al. A lineage of myeloid cells independent of Myb and hematopoietic stem cells. Science 2012, 336:86-90.
38. Gosselin D., et al. Environment drives selection and function of enhancers controlling tissue-specific macrophage identities. Cell 2014, 159:1327-1340.
39. Lavin Y., et al. Tissue-resident macrophage enhancer landscapes are shaped by the local microenvironment. Cell 2014, 159:1312-1326.
40. Palazuelos J., et al. Microglial CB2 cannabinoid receptors are neuroprotective in Huntington's disease excitotoxicity. Brain 2009, 132:3152-3164.
41. Bouchard J., et al. Cannabinoid receptor 2 signaling in peripheral immune cells modulates disease onset and severity in mouse models of Huntington's disease. J. Neurosci. 2012, 32:18259-18268.
42. Sagredo O., et al. Cannabinoid CB2 receptor agonists protect the striatum against malonate toxicity: relevance for Huntington's disease. Glia 2009, 57:1154-1167.
43. Valdeolivas S., et al. Sativex-like combination of phytocannabinoids is neuroprotective in malonate-lesioned rats, an inflammatory model of Huntington's disease: role of CB1 and CB2 receptors. ACS Chem. Neurosci. 2012, 3:400-406.
44. Dowie M.J., et al. Cannabinoid receptor CB2 is expressed on vascular cells, but not astroglial cells in the post-mortem human Huntington's disease brain. J. Chem. Neuroanat. 2014, 59-60:62-71.
45. Singhrao S.K., et al. Increased complement biosynthesis by microglia and complement activation on neurons in Huntington's disease. Exp. Neurol. 1999, 159:362-376.
46. Larkin P.B., Muchowski P.J. Genetic deficiency of complement Component 3 does not alter disease progression in a mouse model of Huntington's disease. J. Huntingtons Dis. 2012, 1:107-118.
47. Stevens B., et al. The classical complement cascade mediates CNS synapse elimination. Cell 2007, 131:1164-1178.
48. Schafer D.P., et al. Microglia sculpt postnatal neural circuits in an activity and complement-dependent manner. Neuron 2012, 74:691-705.
49. Chu Y., et al. Enhanced synaptic connectivity and epilepsy in C1q knockout mice. Proc. Natl. Acad. Sci. U.S.A. 2010, 107:7975-7980.
50. Hands S., et al. In vitro and in vivo aggregation of a fragment of huntingtin protein directly causes free radical production. J. Biol. Chem. 2011, 286:44512-44520.
51. Wyttenbach A., et al. Heat shock protein 27 prevents cellular polyglutamine toxicity and suppresses the increase of reactive oxygen species caused by huntingtin. Hum. Mol. Genet. 2002, 11:1137-1151.
52. Fox J.H., et al. Cysteine oxidation within N-terminal mutant huntingtin promotes oligomerization and delays clearance of soluble protein. J. Biol. Chem. 2011, 286:18320-18330.
53. Block M.L., et al. Microglia-mediated neurotoxicity: uncovering the molecular mechanisms. Nat. Rev. Neurosci. 2007, 8:57-69.
54. Barja G. Free radicals and aging. Trends Neurosci. 2004, 27:595-600.
55. Shirendeb U., et al. Abnormal mitochondrial dynamics, mitochondrial loss and mutant huntingtin oligomers in Huntington's disease: implications for selective neuronal damage. Hum. Mol. Genet. 2011, 20:1438-1455.
56. Hilditch-Maguire P., et al. Huntingtin: an iron-regulated protein essential for normal nuclear and perinuclear organelles. Hum. Mol. Genet. 2000, 9:2789-2797.
57. Firdaus W.J., et al. Huntingtin inclusion bodies are iron-dependent centers of oxidative events. FEBS J. 2006, 273:5428-5441.
58. Simmons D.A., et al. Ferritin accumulation in dystrophic microglia is an early event in the development of Huntington's disease. Glia 2007, 55:1074-1084.
59. Curtis A.R., et al. Mutation in the gene encoding ferritin light polypeptide causes dominant adult-onset basal ganglia disease. Nat. Genet. 2001, 28:350-354.
60. Rhee S.G., et al. Peroxiredoxins: a historical overview and speculative preview of novel mechanisms and emerging concepts in cell signaling. Free Radic. Biol. Med. 2005, 38:1543-1552.
61. Mason R.P., et al. Glutathione peroxidase activity is neuroprotective in models of Huntington's disease. Nat. Genet. 2013, 45:1249-1254.
62. Schwarcz R., et al. Of mice, rats and men: revisiting the quinolinic acid hypothesis of Huntington's disease. Prog. Neurobiol. 2009, 90:230-245.
63. Beal M.F., et al. Kynurenine pathway measurements in Huntington's disease striatum: evidence for reduced formation of kynurenic acid. J. Neurochem. 1990, 55:1327-1339.
64. Giorgini F., et al. A genomic screen in yeast implicates kynurenine 3-monooxygenase as a therapeutic target for Huntington disease. Nat. Genet. 2005, 37:526-531.
65. Guillemin G.J., et al. Expression of the kynurenine pathway enzymes in human microglia and macrophages. Adv. Exp. Med. Biol. 2003, 527:105-112.
66. Giorgini F., et al. Histone deacetylase inhibition modulates kynurenine pathway activation in yeast, microglia. and mice expressing a mutant huntingtin fragment. J. Biol. Chem. 2008, 283:7390-7400.
67. Jia H., et al. HDAC inhibition imparts beneficial transgenerational effects in Huntington's disease mice via altered DNA and histone methylation. Proc. Natl. Acad. Sci. U.S.A. 2015, 112:E56-E64.
68. Sofroniew M.V., Vinters H.V. Astrocytes: biology and pathology. Acta Neuropathol. 2010, 119:7-35.
69. Chen Y., Swanson R.A. Astrocytes and brain injury. J. Cereb. Blood Flow Metab. 2003, 23:137-149.
70. Saijo K., et al. A Nurr1/CoREST pathway in microglia and astrocytes protects dopaminergic neurons from inflammation-induced death. Cell 2009, 137:47-59.
71. Chung W.S., et al. Astrocytes mediate synapse elimination through MEGF10 and MERTK pathways. Nature 2013, 504:394-400.
72. Loov C., et al. Engulfing astrocytes protect neurons from contact-induced apoptosis following injury. PLoS ONE 2012, 7:e33090.
73. Lievens J.C., et al. Impaired glutamate uptake in the R6 Huntington's disease transgenic mice. Neurobiol. Dis. 2001, 8:807-821.
74. Shin J.Y., et al. Expression of mutant huntingtin in glial cells contributes to neuronal excitotoxicity. J. Cell Biol. 2005, 171:1001-1012.
75. Estrada-Sanchez A.M., Rebec G.V. Corticostriatal dysfunction and glutamate transporter 1 (GLT1) in Huntington's disease: interactions between neurons and astrocytes. Basal Ganglia 2012, 2:57-66.
76. Bradford J., et al. Expression of mutant huntingtin in mouse brain astrocytes causes age-dependent neurological symptoms. Proc. Natl. Acad. Sci. U.S.A. 2009, 106:22480-22485.
77. Chou S.Y., et al. Expanded-polyglutamine huntingtin protein suppresses the secretion and production of a chemokine (CCL5/RANTES) by astrocytes. J. Neurosci. 2008, 28:3277-3290.
78. Spires T.L., et al. Dendritic spine pathology and deficits in experience-dependent dendritic plasticity in R6/1 Huntington's disease transgenic mice. Eur. J. Neurosci. 2004, 19:2799-2807.
79. Ariano M.A., et al. Striatal potassium channel dysfunction in Huntington's disease transgenic mice. J. Neurophysiol. 2005, 93:2565-2574.
80. Tong X., et al. Astrocyte Kir4.1 ion channel deficits contribute to neuronal dysfunction in Huntington's disease model mice. Nat. Neurosci. 2014, 5:694-703.
81. Hsiao H.Y., et al. A critical role of astrocyte-mediated nuclear factor-kappaB-dependent inflammation in Huntington's disease. Hum. Mol. Genet. 2013, 22:1826-1842.
82. Hsiao H.Y., et al. Inhibition of soluble tumor necrosis factor is therapeutic in Huntington's disease. Hum. Mol. Genet. 2014, 23:4328-4344.
83. Alto L.T., et al. AAV-dominant negative tumor necrosis factor (DN-TNF) gene transfer to the striatum does not rescue medium spiny neurons in the YAC128 mouse model of Huntington's disease. PLoS ONE 2014, 9:e96544.
84. Ben Haim L., et al. The JAK/STAT3 pathway is a common inducer of astrocyte reactivity in Alzheimer's and Huntington's diseases. J. Neurosci. 2015, 35:2817-2829.
85. Trager U., et al. HTT-lowering reverses Huntington's disease immune dysfunction caused by NFkappaB pathway dysregulation. Brain 2014, 137:819-833.
86. Di Pardo A., et al. Changes of peripheral TGF-beta1 depend on monocytes-derived macrophages in Huntington disease. Mol. Brain 2013, 6:55.
87. Kwan W., et al. Mutant huntingtin impairs immune cell migration in Huntington disease. J. Clin. Invest. 2012, 122:4737-4747.
88. Trager U., et al. Characterisation of immune cell function in fragment and full-length Huntington's disease mouse models. Neurobiol. Dis. 2014, 73C:388-398.
89. Qin L., et al. Systemic LPS causes chronic neuroinflammation and progressive neurodegeneration. Glia 2007, 55:453-462.
90. Kwan W., et al. Bone marrow transplantation confers modest benefits in mouse models of Huntington's disease. J. Neurosci. 2012, 32:133-142.
91. Morten I.J., et al. Investigation into the role of macrophages in the formation and degradation of beta2-microglobulin amyloid fibrils. J. Biol. Chem. 2007, 282:29691-29700.
92. Yang W., et al. Aggregated polyglutamine peptides delivered to nuclei are toxic to mammalian cells. Hum. Mol. Genet. 2002, 11:2905-2917.
93. Cicchetti F., et al. Mutant huntingtin is present in neuronal grafts in Huntington's disease patients. Ann. Neurol. 2014, 1:31-42.
94. Pecho-Vrieseling E., et al. Transneuronal propagation of mutant huntingtin contributes to non-cell autonomous pathology in neurons. Nat. Neurosci. 2014, 17:1064-1072.
95. Wang N., et al. Neuronal targets for reducing mutant huntingtin expression to ameliorate disease in a mouse model of Huntington's disease. Nat. Med. 2014, 20:536-541.
96. Gu X., et al. Pathological cell-cell interactions are necessary for striatal pathogenesis in a conditional mouse model of Huntington's disease. Mol. Neurodegener. 2007, 2:8.
97. Jonsson T., et al. Variant of TREM2 associated with the risk of Alzheimer's disease. N. Engl. J. Med. 2013, 368:107-116.
98. Takahashi K., et al. Clearance of apoptotic neurons without inflammation by microglial triggering receptor expressed on myeloid cells-2. J. Exp. Med. 2005, 201:647-657.
99. Kleinberger G., et al. TREM2 mutations implicated in neurodegeneration impair cell surface transport and phagocytosis. Sci. Transl. Med. 2014, 6:243ra86.
100. Wang Y., et al. TREM2 lipid sensing sustains the microglial response in an Alzheimer's disease model. Cell 2015, 160:1061-1071.
101. Griciuc A., et al. Alzheimer's disease risk gene CD33 inhibits microglial uptake of amyloid beta. Neuron 2013, 78:631-643.
102. Heneka M.T., et al. Neuroinflammation in Alzheimer's disease. Lancet Neurol. 2015, 14:388-405.
103. Mosher K.I., Wyss-Coray T. Microglial dysfunction in brain aging and Alzheimer's disease. Biochem. Pharmacol. 2014, 88:594-604.
104. Zuccato C., Cattaneo E. Huntington's disease. Handb. Exp. Pharmacol. 2014, 220:357-409.